Review Article
PET and PET/CT with 68Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
Table 3
Summary of the role of positron emission tomography and positron emission tomography/computed tomography with 68Ga-radiolabeled somatostatin analogues in tumors other than gastroenteropancreatic neuroendocrine tumors.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PET: positron emission tomography; PET/CT: positron emission tomography/computed tomography; PRRT: peptide radioreceptor therapy; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; MTC: medullary thyroid cancer; DTC: differentiated thyroid cancer. Based on literature data we classified the use of radiolabeled somatostatin-analogues PET or PET/CT as ++: suitable; +: promising; +/−: undetermined; and −: not indicated. |